| Autor: |
Pachiega J; Universidade do Estado de Mato Grosso, Faculdade de Ciências da Saúde, Departamento de Medicina, Cáceres, Mato Grosso, Brazil., Afonso AJDS; Universidade do Estado de Mato Grosso, Faculdade de Ciências da Saúde, Departamento de Medicina, Cáceres, Mato Grosso, Brazil., Sinhorin GT; Universidade do Estado de Mato Grosso, Faculdade de Ciências da Saúde, Departamento de Medicina, Cáceres, Mato Grosso, Brazil., Alencar BT; Universidade do Estado de Mato Grosso, Faculdade de Ciências da Saúde, Departamento de Enfermagem, Cáceres, Mato Grosso, Brazil., Araújo MDSM; Universidade do Estado de Mato Grosso, Faculdade de Ciências Agrárias e Biológicas, Programa de Pós-Graduação em Ciências Ambientais, Cáceres, Mato Grosso, Brazil., Longhi FG; Centro de Excelência do Instituto Joanna Briggs, Centro Brasileiro para o Cuidado à Saúde Informado por Evidências, São Paulo, São Paulo, Brazil., Zanetti ADS; Universidade do Estado de Mato Grosso, Faculdade de Ciências Agrárias e Biológicas, Programa de Pós-Graduação em Ciências Ambientais, Cáceres, Mato Grosso, Brazil., Espinosa OA; Faculdade do Pantanal, Cáceres, Mato Grosso, Brazil. |
| Abstrakt: |
Age, sex and presence of comorbidities are risk factors associated with COVID-19. Hypertension, diabetes and heart disease are the most common comorbidities in patients with COVID-19. The objective of this study was to estimate the prevalence of patients with comorbidities who died of COVID-19 in Brazil. Searches of data were carried out on the official pages of the 26 State health departments and the federal district. The random-effect method was used to calculate the prevalence of patients with comorbidities who died. From the beginning of the pandemic in Brazil until May 20, 2020, 276,703 cases of COVID-19 were notified in Brazil, 6.4% died, 58.6% of whom were male. The prevalence of comorbidities among deaths was 83% (95% CI: 79 - 87), with heart disease and diabetes being the most prevalent. To our knowledge, this study represents the first large analysis of cases of patients with confirmed COVID-19 in Brazil. There is a high prevalence of comorbidities (83%) among patients who died from COVID-19 in Brazil, with heart disease being the most prevalent. This is important considering the possible secondary effects produced by drugs such as hydroxychloroquine. |
